Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.21 USD | -7.58% | -3.55% | +22.11% |
Sales 2024 * | 22.15M 27.74M | Sales 2025 * | 36.37M 45.53M | Capitalization | 790M 989M |
---|---|---|---|---|---|
Net income 2024 * | -42M -52.59M | Net income 2025 * | -72M -90.15M | EV / Sales 2024 * | 31.5 x |
Net cash position 2024 * | 91.29M 114M | Net cash position 2025 * | 82.95M 104M | EV / Sales 2025 * | 19.4 x |
P/E ratio 2024 * |
-45.4
x | P/E ratio 2025 * |
-32.6
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
1 day | -7.58% | ||
1 week | -3.55% | ||
Current month | -2.97% | ||
1 month | -5.14% | ||
3 months | -3.77% | ||
6 months | +130.54% | ||
Current year | +22.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 21-01-05 |
Director of Finance/CFO | 52 | 21-03-31 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-07-28 |
David Lemus
BRD | Director/Board Member | 61 | 18-06-20 |
Iain Ross
CHM | Chairman | 71 | 04-07-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 21.21 | -7.58% | 54,573 |
24-05-09 | 22.95 | +1.55% | 189,822 |
24-05-08 | 22.6 | +1.85% | 119,682 |
24-05-07 | 22.19 | +1.32% | 87,830 |
24-05-06 | 21.9 | -0.41% | 47,051 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- SLN Stock